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Abstract: Pregabalin is an anticonvulsant used for the treatment of neuropathic pain and 
partial seizure in adults. The aim of this study was to develop a population pharmacokinetic 
(PK) model to describe the absorption characteristics of pregabalin given fasted or after 
meals. Data from five healthy subject PK studies (n=88) of single- or multiple-dose pregabalin 
(150 mg) were used. Pregabalin was administered twice daily, without meals or 30 min after 
a meal (regular or high-fat diet) in the morning and 30 min or 4 h after a meal (regular diet) 
in the evening. Serial plasma samples were collected up to 24 h after the last dose for PK 
analysis. Because the peak concentrations were not properly modeled by a conventional 
first-order absorption model, Erlang frequency distribution, Weibull-type absorption, and 
transit compartment models were tested on a two-compartment linear PK model using a 
nonlinear mixed-effects method (NONMEM; version 7.3). The transit compartment model 
best described the absorption characteristics of pregabalin regardless of meal status. We con-
clude that the absorption model should be carefully chosen based on the principle of model 
development and validation and not by following a conventional first-order absorption model 
for its popularity and simplicity, especially when the PK dataset includes densely sampled 
absorption-phase data.
Keywords: absorption, NONMEM, pregabalin, transit compartment model
Introduction
Pregabalin, an analog of gamma-aminobutyric acid, binds to the α2δ subunit of 
a voltage-dependent calcium channel in the central nervous system1 and reduces 
calcium influx at nerve terminals, thereby decreasing the release of neurotransmitters 
such as glutamate, noradrenaline, and substance P.2–4 For these mechanisms of action, 
pregabalin has been prescribed worldwide for partial-onset seizure, generalized anxiety 
disorder, and neuropathic pain disorders since 2005.
The pharmacokinetic (PK) characteristics of an oral pregabalin immediate-release 
formulation have been extensively studied. Pregabalin is rapidly absorbed in the fasting 
state, with peak plasma concentrations occurring within 1 h. Food reduces the absorp-
tion rate, resulting in lowered and delayed maximum plasma concentration without a 
clinically significant effect on the extent (bioavailability).5 A few studies on the popu-
lation PK of pregabalin have been conducted;6–8 these studies commonly employed 
a one-compartment model with first-order absorption and elimination only without 
mentioning any attempt to find a better model. However, in these studies, a common 
trend to underestimate pregabalin concentrations around the time of maximum plasma 
concentration (T
max
) was observed, which suggests the possibility of an inappropriate 
choice of absorption model (first-order absorption).
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Recently, we conducted several PK studies on healthy 
subjects to compare a reference (Lyrica® 150 mg; Pfizer, 
Inc., New York, NY, USA) and sustained release formulation 
of pregabalin developed by domestic companies in Korea. 
Single- and multiple-dose PK data (fasted or fed) of the 
reference formulation of pregabalin from these studies were 
analyzed to find an absorption model that best describes the 
peak concentrations. The aim of this study was to develop a 
population PK model to describe the absorption character-
istics of pregabalin given after fasting or food.
Materials and methods
studies and subjects
PK data from 88 healthy male subjects in five different 
studies performed at the clinical trial center, Seoul St Mary’s 
Hospital in Korea, were used for the population PK analysis. 
We enrolled healthy Korean male volunteers meeting the 
following eligibility criteria: age 20–45 years, weight within 
20% of ideal body weight (IBW), and no clinically significant 
abnormalities. Individuals were excluded if they had any 
history or evidence of disease in the major organ systems or 
any other acute or chronic disease. Individuals who donated 
blood within 2 months of the first blood sampling were also 
excluded, irrespective of the amount. Subjects abstained 
from drugs, foods, and any other lifestyle factors that might 
alter the PK characteristics of pregabalin for at least 2 weeks 
before and throughout the participation. The demographic 
characteristics, such as age, weight, and creatinine clearance 
(CLCR), between studies were not found to be significantly 
different using a Kruskal–Wallis test (SAS version 9.4; SAS 
Institute Inc., Cary, NC, USA). The subjects’ demographics 
are summarized in Table 1. All the studies were designed 
and monitored in accordance with Korean Good Clinical 
Practice guidelines and the principles of the Declaration 
of Helsinki. The independent institutional review board of 
Seoul St Mary’s Hospital approved the protocols before the 
start of the trials, and all subjects provided written informed 
consent to participate.
study design and blood sampling
The study design, dosing regimen, and type of meals for 
the five studies are presented in Table 2. Peripheral venous 
blood was tightly sampled into ethylenediaminetetraacetic 
acid-containing tubes (Vacutainer; BD Belliver Industrial 
Estate, Plymouth, UK) up to 24 h after a single dose or the 
last dose at a steady state. The PK sampling time points for 
each study are summarized in Table 2. Plasma was separated 
immediately by centrifugation at 3,000× g for 10 min at 4°C 
and stored at −70°C until pregabalin was assayed.
assay of pregabalin plasma concentration
The plasma concentration of pregabalin was assayed by 
validated methods using high-performance liquid chro-
matography coupled with tandem mass spectrometry 
(LC/MS/MS).9 The assay method was as follows. Plasma 
(100 μL) was precipitated with methanol containing an 
internal standard. After thoroughly vortexing for ~1 min, the 
samples were centrifuged at 12,000–13,000× g for 8–10 min 
at 4°C. The supernatant was diluted with methanol, and then 
1–2 μL was injected into the LC/MS/MS system. Plasma 
concentrations were determined using four different ana-
lytical contract research organizations (CROs). The assay 
conditions including instruments were slightly different 
between the CROs (Table 3).
Population PK model development
PK analysis with the mixed-effects modeling method 
was conducted using a nonlinear mixed-effects method 
(NONMEM), version 7.3 (ICON Development Solutions, 
Ellicott City, MD, USA), with the GFortran compiler. The 
dataset consisted of 1,615 pregabalin concentration observa-
tions from the 88 subjects in the five studies.
Basic PK model
The first-order conditional estimation method with inter-
action (FOCE-I) was used throughout the model building 
Table 1 subjects’ demographics (mean ± standard deviation)
Study no 1 2 3 4 5 Total P-valuea
no of subjects 7 16 23 22 20 88 –
age (y) 24.4±2.2 28.3±6.2 28.3±4.9 26.6±4.5 26.8±5.3 27.2±5.0 0.29
Weight (kg) 66.7±6.1 68.4±9.2 69.0±8.0 66.2±6.8 70.3±7.8 68.3±7.8 0.62
clcr (ml/min) 132.8±23.5 124.6±21.3 125.0±25.0 110.8±17.5 116.1±17.8 120.0±21.6 0.12
Note: aKruskal–Wallis test.
Abbreviations: clcr, creatinine clearance; y, years.
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process.10 The between-subject variability (BSV) for each 
parameter was applied exponentially as follows:
 
P exp )
ij j ij
= ×θ (η
 
where P
ij
 is the jth parameter for the ith individual, θ
j
 is the 
typical value of the jth population parameter, and η
ij
 is a 
random variable following a Gaussian distribution with a 
mean of 0 and variance of ω
j
2.
To refine the PK model, the covariance between random 
effects in the model was explored using the OMEGA BLOCK 
option. Additive, proportional, and combined error models 
were tested for residual errors.
The appropriateness of model was evaluated based on 
various goodness-of-fit criteria, including diagnostic scatter 
plots, likelihood ratio test (LRT), and measures of model 
stability and adequacy (condition number, successful conver-
gence, significant digits, and matrix singularity). The residual-
based model diagnostic was performed using conditional 
weighted residuals (CWRES). The results for LRT were 
considered statistically significant if decreases in the objective 
function value (OFV) of nested models were .3.84 (P,0.05, 
one degree of freedom) and 5.99 units (P,0.05, two degrees 
of freedom) throughout the model building process. Besides 
the OFV, the predictive performance of the non-nested 
model was evaluated using the Akaike information criterion 
(AIC), which is expressed as follows:
 AIC OFV p= + 2  
where p is the number of all parameters.
Table 2 study design
Study no Study 
designa
Regimen Meal conditions 
before dosing
Type of meal Number of samples per subject 
(PK sampling time points [h])
1 Pg MD: 150 mg once a day (for 
days 1, 5) and 150 mg every 
12 h for 3 days (for days 2, 3, 4)
30 min after meal regular diet 20 (0, 48, 72, 72.33, 72.67, 73, 73.5, 
74, 75, 78, 84, 84.33, 84.67, 85, 85.5, 
86, 87, 88, 96, 108)
2 2-way XO MD: 150 mg every 12 h for 
3 days
Morning dose: 
overnight fasting
evening dose: 4 h 
after dinner
regular diet 19 (0, 24, 48, 48.33, 48.67, 49, 49.5, 
50, 52, 54, 60, 60.33, 60.67, 61, 61.5, 
62, 64, 72, 84)
3 3-way XO sD: 150 mg every 12 h for 
1 day
Morning dose: 
overnight fasting
evening dose: 4 h 
after dinner
regular diet 17 (0, 0.33, 0.67, 1, 1.5, 2, 4, 6, 12, 
12.33, 12.67, 13, 13.5, 14, 16, 24, 36)
4 2-way XO MD: 150 mg every 12 h for 
3 days
30 min after meal Breakfast: high-fat diet
Dinner: regular diet
20 (0, 24, 48, 48.33, 48.67, 49, 49.5, 
50, 52, 56, 60, 60.33, 60.67, 61, 61.5, 
62, 64, 68, 72, 84)
5 2-way XO sD: 150 mg every 12 h for 
1 day
30 min after meal regular diet 17 (0, 0.33, 0.67, 1, 1.5, 2, 4, 6, 12, 
12.33, 12.67, 13, 13.5, 14, 16, 24, 36)
Note: aall studies were randomized and open labeled.
Abbreviations: MD, multiple dose; Pg, parallel group; PK, pharmacokinetic; sD, single dose; XO, crossover.
Table 3 analysis information
Study no HPLC Mass spectrometer LLOQ (ng/mL) Accuracy (%) Precision (CV%)
1 lc-20aD (shimadzu, 
Tokyo, Japan)
aPi 5000 Triple Quadrupole (Thermo 
Fisher Scientific, Waltham, MA, USA)
30 98.8–103.5 0.80–4.70
2 agilent 1200 series  
(agilent Technologies, santa 
clara, ca, Usa)
aPi 3200 (scieX, redwood city, ca, 
Usa)
50 96.3–103.0 0.40–2.70
3 agilent 1200 series  
(agilent Technologies)
aPi 3200 (scieX) 50 96.3–103.0 0.40–2.70
4 agilent 1260 solvent Delivery 
system (agilent Technologies)
agilent 6460 series Triple 
Quadrupole (agilent Technologies)
50 99.2–102.4 0.20–2.80
5 agilent 1200 series  
(agilent Technologies)
agilent 6460 series Triple 
Quadrupole (agilent Technologies)
100 98.1–103.4 0.52–1.91
Abbreviations: CV, coefficient of variation; HPLC, high-performance liquid chromatography; LLOQ, lower limit of quantification.
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Both the one- and two-compartment models were tested, 
and all PK processes (except absorption) were assumed 
to follow first-order kinetics. The first-order rate constant 
and zero-order input (with or without lag time), Erlang 
frequency distribution,11 transit compartment,12 and Weibull-
type absorption models13 were tested to determine the best 
description of the absorption profile of fasted and fed states. 
Because our drug concentration data include multiple-dose 
administration, we introduced the concept of dose superim-
position to apply the transit compartment or Weibull-type 
absorption models.14
covariate selection
Demographic and clinical variables, such as age, weight, 
IBW,15 and CLCR, calculated with the Cockcroft–Gault 
equation16 and fasted/fed status were tested as potential 
covariates for PK parameters.
Both visual (parameter vs covariate scatter plots) and 
numerical (generalized additive model in Xpose, version 
4.0.4) covariate screening procedures were performed before 
adding each covariate to the basic model. Covariates that 
passed either of the screening procedures were subsequently 
tested in the model. Covariates were chosen using forward 
selection–backward elimination with the LRT.
Model evaluation
A bootstrap resampling method was used to evaluate the sta-
bility and robustness of the final PK model. Resampling with 
replacement generated 1,000 bootstrap datasets, and the final 
population PK model was fitted repeatedly to each of the 1,000 
bootstrap datasets. The median and 95% confidence intervals 
of parameters obtained from this step were compared with the 
final parameter estimates. In addition, a visual predictive check 
(VPC) with 1,000 simulated datasets was also performed. 
Results from the VPC were assessed using graphical compari-
son of the simulated data overlaid observed data.
Results
Population PK model
The OFV results obtained from the different structural mod-
els tested are summarized in Table 4. A two-compartment 
model with first-order elimination and proportional residual 
error was chosen as the basic PK model. The OMEGA 
BLOCK structure between apparent clearance (CL/F) and 
apparent central compartment volume incorporated into the 
basic model was maintained throughout the model develop-
ment process. The absorption profile of pregabalin was best 
described by the transit compartment model that resulted 
in a significant improvement in the AIC compared with the 
first-order absorption model (ΔAIC, 497.3) or the Erlang 
frequency distribution model (ΔAIC, 8.5) and better per-
formance in the visual exploration of diagnostic plots. The 
average and maximal η shrinkage values of the final model 
parameters were 26.3% and 37.2%, respectively.
The goodness-of-fit plots of the transit compartment 
model are shown in Figure 1. The distribution pattern of 
CWRES at individual T
max
 also showed the outperformance 
of the transit compartment model (Figure 2).
Because the absorption profile for the PK data obtained 
after overnight fasting was markedly different from that after 
a meal, the absorption parameters were estimated separately 
(Table 5). However, details such as dosing time differences 
after meals (30 min after versus 4 h after a meal) were not 
successfully modeled. The relative bioavailability changes 
caused by meals were not considered in the model because 
the changes were not acknowledged in the statistical tests of 
linear-trapezoidal area under the curves (AUCs; not shown 
in this report). CLCR on CL was the only covariate incor-
porated into the model.
Model evaluation
The VPC plots from the final population PK models using the 
first-order absorption and transit compartment models were 
Table 4 comparison of the tested models
No Model tested No of parametersa OFV CL/F (L/h) V/F (L)b
1 First-order absorption + one compartment 10 18,670.37 6.53 46.2
2 First-order absorption + one compartment + lag time 12 18,211.86 6.36 46.8
3 First-order absorption + two compartments + lag time 15 18,137.27 6.43 47.2
4 Zero-order input + two compartments 13 18,089.94 6.25 47.3
5 Erlang frequency + two compartments  
(four sequential compartments)
15 17,648.44 6.24 45.3
6 Transit compartment + two compartments  
(nn =3.61): final model
17 17,635.99 6.25 44.9
Notes: aSum of fixed effects and random effects. bsum of central volume and peripheral volume.
Abbreviations: cl/F, apparent clearance; nn, number of transit compartment; OFV, objective function value; V/F, apparent volume of distribution.
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overlaid for comparison (Figure 3). Although the superiority 
of the transit compartment model was clear before testing 
covariates, we continued to build models using the first-order 
absorption model to compare the performance of final models 
built using different absorption models. Therefore, the first-
order absorption model used to draw the VPC plot had the 
CLCR as its covariate as did the final transit compartment 
model that was compared in the same graph.
    





2EV
HUYD
WLRQ
QJ
P/

3RSXODWLRQSUHGLFWLRQQJP/     





,QGLYLGXDOSUHGLFWLRQQJP/
2EV
HUYD
WLRQ
QJ
P/

,QGLYLGXDOSUHGLFWLRQQJP/   





,:5
(6

   7LPHDIWHUGRVHK   
&:
5(6 
±


Figure 1 Goodness-of-fit plots for the final population transit compartment PK model for pregabalin.
Note: Black line, line of identity; gray line, lOess line.
Abbreviations: cWres, conditional weighted residuals; iWres, individual weighted residuals; PK, pharmacokinetic; lOess, locally weighted scatterplot smoothing.
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Figure 2 CWRES of first-order absorption model and transit compartment model at peak concentrations (left) and trough concentrations (right).
Abbreviation: cWres, conditional weighted residuals.
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The location of the median and lower 5th percentile 
curves in comparison with the observed concentration spots 
scattered in the panels indicated better performance of the 
transit compartment model than the first-order absorption 
model. The median parameter estimates obtained from the 
1,000 bootstrap data sets were very similar to the estimates 
of the final model, as summarized in Table 5.
Discussion
In this study, we sought to develop a population PK model 
for pregabalin based on our data, without following the 
population PK model previously used. We found that 
the pregabalin PK in our data was best described by two-
compartment distribution and transit compartment absorp-
tion model.
There is a time delay between pregabalin exposure and 
response as a result of its binding to the calcium channel 
in the central nervous system that is consistent with con-
siderable time lags between T
max
 of cerebrospinal fluid and 
plasma.17 Bender et al18 adopted an effect compartment 
model to analyze the static allodynia response to pregabalin 
in rats with neuropathic pain. Accurate prediction of peak 
concentrations is pivotal in the effect compartment model 
approach. A pooled analysis of 11 clinical studies found 
that the relative risk of most common adverse events 
increased with the dose of pregabalin.19 Because the peak 
concentrations of pregabalin are dose proportional, they 
are closely related to adverse events. Therefore, proper 
description of the absorption process is crucial to evaluate 
efficacy and safety.
The absorption process of drug is complicated and 
influenced by many physiological factors, but the PK models 
frequently used are rather simple. In most cases, modelers 
seem to use first- or zero-order (with or without lag time) 
models without testing others. However, when these con-
ventional models do not seem to properly describe the 
absorption profile, others such as the transit compartment 
or Weibull-type absorption can be considered. Gamma 
distribution, which is used in the transit compartment 
model, has the advantage of accounting for the concave-
shaped time–concentration curves in the absorption phase; 
in other words, the absorption rate increases over time.20 
This flexibility of the transit compartment model makes it 
possible to describe uncommon situations, such as the longer 
Table 5 Final estimates of population PK parameters
Parameter Description (unit) Estimate % RSE Bootstrap median 
(95% CI)a
Fixed effect
cl/F = clt/F × (clcr/120)θclcr apparent clearance (l/h)
clt/F Typical value of apparent clearance (l/h) 6.25 0.80 6.25 (6.08–6.42)
θclcr exponent of mean-normalized clcr 0.511 8.96 0.509 (0.405–0.601)
V2/F apparent volume of central compartment (l) 18.0 1.78 17.7 (4.65–22.7)
Q/F apparent intercompartmental clearance (l/h) 26.5 3.63 26.5 (19.9–43.5)
V3/F apparent volume of peripheral compartment (l) 27.0 1.93 27.2 (23.3–37.7)
MTTfast MTT of fasting state (h) 0.494 9.94 0.499 (0.411–0.600)
MTTfed MTT of fed state (h) 0.879 6.88 0.884 (0.751–1.101)
nn number of transit compartment 3.61 5.32 3.63 (3.19–4.26)
Kafast absorption rate constant of fasting state (h−1) 5.69 33.57 5.73 (2.94–9.11)
Kafed absorption rate constant of fed state (h−1) 0.713 1.47 0.709 (0.617–0.814)
Random effect (CV%)
ωclt/F BsV of clt/F 11.2 21.1 10.9 (8.6–13.3)
ωV2/F BsV of V2/F 27.8 34.1 27.5 (13.2–60.7)
ωQ/F BsV of Q/F not estimated
ωV3/F BsV of V3/F not estimated
ωMTTfast BsV of MTT of fasting state 43.7 28.8 40.4 (28.5–53.3)
ωMTTfed BsV of MTT of fed state 81.9 10.6 80.9 (70.7–88.9)
ωnn BsV of nn not estimated
ωKa BsV of Ka (fasting and fed) 49.4 21.5 46.2 (36.2–57.1)
ρ −cl /F V2/Ft Correlation coefficient between CLt/F and V2/F 0.615
Residual error
σprop (%) Proportional error 19.0 4.76 17.7 (15.6–19.9)
Note: a95% CI estimated by applying final PK model to 1,000 resampled datasets.
Abbreviations: BSV, between-subject variability; CI, confidence interval; CLCR, creatinine clearance; CV, coefficient of variation; MTT, mean transit time; PK, pharmacokinetic; 
rse, relative standard error.
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duration of absorption, from varying drug input rates along 
the gastrointestinal tract or release of the encapsulated drug 
through dissolution processes. Because a previous dose may 
not be absorbed completely before the next dosing time, we 
used the NONMEM code provided by Shen et al14 to imple-
ment the dose superimposition. We also sought to implement 
Weibull-type absorption for dose superimposition, but failed 
to estimate appropriate parameters.
Estimated population CL/F in the first-order absorption 
model (6.43 L/h) was slightly greater than that of the transit 
compartment model (6.25 L/h). This difference in CL/F may 
have been caused by the underestimated individual predic-
tion (IPRED) concentrations by the first-order absorption 
model in the early absorption phase. In the lag-time IPRED, 
concentrations were 0. However, true concentrations may 
be somewhere between 0 and lower limit of quantifica-
tion (LLOQ). At the T
max
, the IPRED concentrations in the 
first-order absorption model also tended to be lower than 
those in the transit compartment model. This may have 
caused smaller estimated AUC values and therefore larger 
CL/F in the first-order absorption model. The problem 
of the lag time model ignoring initial slow absorption is 
understood in the context that the concept of lag time is not 
physiologically plausible.20
Food significantly decreased the rate of oral absorption in 
the central compartment (rate constant decreased by 87.5% 
compared with overnight fasting) and prolonged mean transit 
time by ~0.39 h; however, differences in food types (high fat 
Figure 3 VPC plots for the first-order absorption model (red line) and transit compartment model (blue line) of study 3 (A), study 5 (B), study 2 (C), and study 1 and 
study 4 (D).
Notes: (A) day 1 (fasted and fed), (B) day 1 (both fed), (C) steady state (fasted and fed), and (D) steady state (both fed). Open circle, observed concentration; solid line, 
median; dashed line, fifth and 95th percentiles; and gray areas, 90% CIs of observed concentrations.
Abbreviations: VPC, visual predictive check; CI, confidence interval.
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or regular) or time after meal (0.5 h versus 4 h) were not 
significantly different or discernible.
The population CL/F of pregabalin in the reports by 
Bockbrader et al6 and Shoji et al7 proportionally increased 
with CLCR up to a breakpoint of 107 mL/min (0.0464 or 
0.0462× CLCR as mL/min) and remained unchanged beyond 
this point. However, such a breakpoint was not found in 
data from our healthy subjects. As illustrated in Figure 4, 
the individual predicted CL/F in the final model increased 
with CLCR without showing any saturation or breakpoint-
like pattern around the CLCR 107 mL/min, which may have 
resulted from the relatively smaller number and homogeneity 
of the subjects in our study. The population CL/F of 
pregabalin reported previously was 4.96 L/h6 or 4.94 L/h7 
in individuals with a CLCR of 107 mL/min and an IBW of 
62 kg. In a typical individual with the same CLCR, the CL/F 
was predicted to be 5.89 L/h by our transit compartment 
model. Such differences may be attributed to differences in 
subjects (patients vs young healthy male volunteers).
In the datasets used in the references cited above, fasted 
PK datasets densely sampled from healthy volunteers at the 
absorption phase that may show discernible distribution 
phases were included. However, both groups of the investiga-
tors started their model development at the one-compartment 
model with first-order absorption and elimination without 
mentioning further comparison of multicompartment or any 
other absorption models. It is supposed that their population 
analyses were mainly focused on finding structural models 
and covariates for the CL of pregabalin. Although the transit 
compartment model used in the present report is more 
complicated than the simple zero- or first-order absorption 
model, it may be applied for a more precise evaluation of 
safety profiles of drugs when their adverse effects are closely 
related to peak concentrations.
Conclusion
In the present report, we showed that the population 
absorption profile of pregabalin was better described by a 
transit compartment model than by a first-order absorption 
model with lag time. Through the present analysis, we con-
cluded that the absorption model should be carefully chosen 
based on the principle of model development and validation, 
as opposed to following a conventional model for popularity 
and simplicity, especially when the PK dataset includes 
densely sampled absorption-phase data.
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